Drugs / Measles-Rubella combined vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT02643433 | Aug 2015 → Jun 2016 | Japanese encephalitis, measles, rubella | Centers for Disease Control and Prevention, China | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT03373656 | May 2017 → Jul 2025 | childhood neoplasm, hematopoietic and lymphoid cell neoplasm | Children's Cancer Group, China | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | measles-rubella combined vaccine | “There are two vaccines provided in this study: hepatitis B vaccine measles-rubella combined vaccine” NCT03373656 ↗ |
| Known as | measles-rubella vaccine | “Enrolled infants were randomly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine...” PMID 30833160 ↗ Mar 2019 |
| Modality | Vaccine | “measles-rubella vaccine” PMID 30833160 ↗ Mar 2019 |
| Route | Subcutaneous | “be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm” NCT02643433 ↗ |